No Data
The 19% Return This Week Takes Ascendis Pharma's (NASDAQ:ASND) Shareholders Three-year Gains to 29%
The Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results Are Out And Analysts Have Published New Forecasts
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $220
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $168 to $225
Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...
Top Gap Ups and Downs on Thursday: APP, SONY, TTD and More
factors that put the rise on are not from a rebound but from news, either way the price is above the price before financial reporting
